Related Experiment Videos
In vitro study on sustained release capsule formulation of acetazolamide
V P Pandey1, K Kannan, R Manavalan
1Department of Pharmacy, Annamalai University, India.
Bollettino Chimico Farmaceutico
|March 26, 2004
Summary
This study developed a sustained-release acetazolamide capsule using nonpareil seeds. The novel formulation demonstrated comparable or superior in vitro performance to marketed products, indicating stability and efficacy.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Acetazolamide is a carbonic anhydrase inhibitor used for various medical conditions.
- Developing sustained-release formulations can improve patient compliance and therapeutic outcomes.
Purpose of the Study:
- To formulate and evaluate a 250 mg sustained-release acetazolamide capsule using nonpareil seeds.
- To compare the in vitro performance of the developed formulation with theoretical and marketed products.
Main Methods:
- Nonpareil seeds were coated with acetazolamide and various excipients (polyvinylpyrrolidone, glyceryl monostearate, microcrystalline wax, glyceryl distearate).
- A successful formulation comprised 20% drug-coated pellets and 80% wax-coated pellets (microcrystalline wax and glyceryl distearate).
- In vitro dissolution studies and stability testing (room temperature, 45°C for 5 weeks) were conducted.
Main Results:
- The optimized formulation achieved sustained release of acetazolamide 250 mg.
- In vitro studies showed the formulated capsule was superior to or on par with the marketed sustained-release capsule.
- The formulation exhibited stability in terms of drug content and release rate under tested conditions.
Conclusions:
- A stable and effective sustained-release acetazolamide 250 mg capsule formulation was successfully developed using nonpareil seeds.
- The novel formulation offers a promising alternative to existing sustained-release options.